Cargando…

Prognostic and therapeutic implication of m6A methylation in Crohn disease

N6-methyladenosine (m6A) methylation has been reported to participate in inflammatory bowel disease (including Crohn disease [CD]). However, the prognostic and therapeutic implication of m6A methylation modification in CD is still unclear. METHODS: Genomic information of CD patients was integrated t...

Descripción completa

Detalles Bibliográficos
Autores principales: He, Yujin, Hu, Yonghui, Yuan, Mei, Xu, Weiwei, Du, Yaqin, Liu, Jinguo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794314/
https://www.ncbi.nlm.nih.gov/pubmed/36595818
http://dx.doi.org/10.1097/MD.0000000000032399
_version_ 1784860011602640896
author He, Yujin
Hu, Yonghui
Yuan, Mei
Xu, Weiwei
Du, Yaqin
Liu, Jinguo
author_facet He, Yujin
Hu, Yonghui
Yuan, Mei
Xu, Weiwei
Du, Yaqin
Liu, Jinguo
author_sort He, Yujin
collection PubMed
description N6-methyladenosine (m6A) methylation has been reported to participate in inflammatory bowel disease (including Crohn disease [CD]). However, the prognostic and therapeutic implication of m6A methylation modification in CD is still unclear. METHODS: Genomic information of CD patients was integrated to assess disease-related m6A regulators, and difference and correlation analyses of m6A regulators were explored by using the R packages. Next, CD patients were classified by the expression of differential and intersecting genes in m6A regulators, and difference and correlation analyses were conducted among immune infiltration and therapeutic responses. Finally, colon tissue resected from patients with CD were assessed to verify expression of Wilms tumor 1-associated protein (WTAP) and METTL14 from these m6A regulators. RESULTS: We identified 23 m6A regulators in CD patients. Difference analysis of these regulators showed that expression of METTL14, WTAP, RBM15 and YTHDF2/3 was upregulated in the treatment group compared with the control group, with expression of METTL3, YTHDF1, leucine-rich pentatricopeptide repeat motif-containing protein, HNRNPA2B1, IGF2BP1 and fat mass and obesity-associated protein downregulated. Moreover, RBM15, WTAP, leucine-rich pentatricopeptide repeat motif-containing protein, YTHDF1 and YTHDF3 were considered the characteristic genes of CD in m6A regulators. In addition, we identified 4 intersection genes of 3 m6A cluster patterns. Based on the expression of these intersection genes, difference analysis among m6A regulators indicated that the expression of 8 m6A regulators had statistical differences among the 3 geneCluster patterns. Assays of colon tissues from CD patients showed that expression of WTAP and METTL14 were higher in areas of stenosis than non-stenosis. CONCLUSION: m6A methylation modification might affect disease risk, immune infiltration and therapeutic responses in CD. Evaluating the expression of m6A regulators might provide insight into the prediction of disease prognosis and therapeutic responses.
format Online
Article
Text
id pubmed-9794314
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-97943142022-12-28 Prognostic and therapeutic implication of m6A methylation in Crohn disease He, Yujin Hu, Yonghui Yuan, Mei Xu, Weiwei Du, Yaqin Liu, Jinguo Medicine (Baltimore) 4500 N6-methyladenosine (m6A) methylation has been reported to participate in inflammatory bowel disease (including Crohn disease [CD]). However, the prognostic and therapeutic implication of m6A methylation modification in CD is still unclear. METHODS: Genomic information of CD patients was integrated to assess disease-related m6A regulators, and difference and correlation analyses of m6A regulators were explored by using the R packages. Next, CD patients were classified by the expression of differential and intersecting genes in m6A regulators, and difference and correlation analyses were conducted among immune infiltration and therapeutic responses. Finally, colon tissue resected from patients with CD were assessed to verify expression of Wilms tumor 1-associated protein (WTAP) and METTL14 from these m6A regulators. RESULTS: We identified 23 m6A regulators in CD patients. Difference analysis of these regulators showed that expression of METTL14, WTAP, RBM15 and YTHDF2/3 was upregulated in the treatment group compared with the control group, with expression of METTL3, YTHDF1, leucine-rich pentatricopeptide repeat motif-containing protein, HNRNPA2B1, IGF2BP1 and fat mass and obesity-associated protein downregulated. Moreover, RBM15, WTAP, leucine-rich pentatricopeptide repeat motif-containing protein, YTHDF1 and YTHDF3 were considered the characteristic genes of CD in m6A regulators. In addition, we identified 4 intersection genes of 3 m6A cluster patterns. Based on the expression of these intersection genes, difference analysis among m6A regulators indicated that the expression of 8 m6A regulators had statistical differences among the 3 geneCluster patterns. Assays of colon tissues from CD patients showed that expression of WTAP and METTL14 were higher in areas of stenosis than non-stenosis. CONCLUSION: m6A methylation modification might affect disease risk, immune infiltration and therapeutic responses in CD. Evaluating the expression of m6A regulators might provide insight into the prediction of disease prognosis and therapeutic responses. Lippincott Williams & Wilkins 2022-12-23 /pmc/articles/PMC9794314/ /pubmed/36595818 http://dx.doi.org/10.1097/MD.0000000000032399 Text en Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 4500
He, Yujin
Hu, Yonghui
Yuan, Mei
Xu, Weiwei
Du, Yaqin
Liu, Jinguo
Prognostic and therapeutic implication of m6A methylation in Crohn disease
title Prognostic and therapeutic implication of m6A methylation in Crohn disease
title_full Prognostic and therapeutic implication of m6A methylation in Crohn disease
title_fullStr Prognostic and therapeutic implication of m6A methylation in Crohn disease
title_full_unstemmed Prognostic and therapeutic implication of m6A methylation in Crohn disease
title_short Prognostic and therapeutic implication of m6A methylation in Crohn disease
title_sort prognostic and therapeutic implication of m6a methylation in crohn disease
topic 4500
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9794314/
https://www.ncbi.nlm.nih.gov/pubmed/36595818
http://dx.doi.org/10.1097/MD.0000000000032399
work_keys_str_mv AT heyujin prognosticandtherapeuticimplicationofm6amethylationincrohndisease
AT huyonghui prognosticandtherapeuticimplicationofm6amethylationincrohndisease
AT yuanmei prognosticandtherapeuticimplicationofm6amethylationincrohndisease
AT xuweiwei prognosticandtherapeuticimplicationofm6amethylationincrohndisease
AT duyaqin prognosticandtherapeuticimplicationofm6amethylationincrohndisease
AT liujinguo prognosticandtherapeuticimplicationofm6amethylationincrohndisease